Cargando…

Treatment of bleeding in acquired hemophilia A with the proper administration of recombinant activated factor VII: single-center study of 7 cases

Recombinant activated factor VII (rFVIIa) is the bypassing agent used in the first-line hemostatic therapy for acquired hemophilia A (AHA); however, the occurrence of thrombotic complications in rFVIIa-treated AHA patients was recently reported to be 2.9–6.5%. Therefore, the investigation of the pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Saito, Makoto, Kanaya, Minoru, Izumiyama, Koh, Mori, Akio, Irie, Tatsuro, Tanaka, Masanori, Morioka, Masanobu, Ieko, Masahiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5098745/
https://www.ncbi.nlm.nih.gov/pubmed/27843336
http://dx.doi.org/10.2147/IJGM.S118422
_version_ 1782465818768965632
author Saito, Makoto
Kanaya, Minoru
Izumiyama, Koh
Mori, Akio
Irie, Tatsuro
Tanaka, Masanori
Morioka, Masanobu
Ieko, Masahiro
author_facet Saito, Makoto
Kanaya, Minoru
Izumiyama, Koh
Mori, Akio
Irie, Tatsuro
Tanaka, Masanori
Morioka, Masanobu
Ieko, Masahiro
author_sort Saito, Makoto
collection PubMed
description Recombinant activated factor VII (rFVIIa) is the bypassing agent used in the first-line hemostatic therapy for acquired hemophilia A (AHA); however, the occurrence of thrombotic complications in rFVIIa-treated AHA patients was recently reported to be 2.9–6.5%. Therefore, the investigation of the proper administration of rFVIIa for AHA is needed. In the present study, we retrospectively investigated the clinical features of AHA with regards to the use of rFVIIa (presence or absence of use and total amount) in 7 AHA patients encountered in our department for 7 years between January 2008 and December 2014. Ages were 63–89 years old (median: 79 years old), and there were 5 male and 2 female patients. The coexistence of cardiovascular risk factors and arteriosclerotic diseases, such as hypertension, diabetes mellitus, and cerebral infarction were present in 6 patients. Anemia progressed to less than 7 g/dL of hemoglobin and required red blood cell transfusion in 5 patients, showing “severe” hemorrhage. Factor VIII inhibitors were removed by immunological treatments in 6 patients. As a hemostatic therapy, rFVIIa was used in 4 patients. rFVIIa was not administered or was administered at a very low dose (20 mg) to 3 and 1 patient, respectively, and bleeding stopped as inhibitor titers decreased and disappeared in these patients. Inhibitors did not disappear in 1 patient and the control of hemostasis became poor and was accompanied by intestinal hemorrhage. Although a large amount of rFVIIa (265 mg in total) was administered, the patient bled to death. Therefore, bleeding may be stopped without the administration of rFVIIa in some AHA cases, while the dose of rFVIIa is not necessarily related to hemostatic effects in other cases. Since the main aim of AHA treatments is the removal of inhibitors, caution is needed to ensure that more than the necessary amount of rFVIIa is not administered.
format Online
Article
Text
id pubmed-5098745
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-50987452016-11-14 Treatment of bleeding in acquired hemophilia A with the proper administration of recombinant activated factor VII: single-center study of 7 cases Saito, Makoto Kanaya, Minoru Izumiyama, Koh Mori, Akio Irie, Tatsuro Tanaka, Masanori Morioka, Masanobu Ieko, Masahiro Int J Gen Med Original Research Recombinant activated factor VII (rFVIIa) is the bypassing agent used in the first-line hemostatic therapy for acquired hemophilia A (AHA); however, the occurrence of thrombotic complications in rFVIIa-treated AHA patients was recently reported to be 2.9–6.5%. Therefore, the investigation of the proper administration of rFVIIa for AHA is needed. In the present study, we retrospectively investigated the clinical features of AHA with regards to the use of rFVIIa (presence or absence of use and total amount) in 7 AHA patients encountered in our department for 7 years between January 2008 and December 2014. Ages were 63–89 years old (median: 79 years old), and there were 5 male and 2 female patients. The coexistence of cardiovascular risk factors and arteriosclerotic diseases, such as hypertension, diabetes mellitus, and cerebral infarction were present in 6 patients. Anemia progressed to less than 7 g/dL of hemoglobin and required red blood cell transfusion in 5 patients, showing “severe” hemorrhage. Factor VIII inhibitors were removed by immunological treatments in 6 patients. As a hemostatic therapy, rFVIIa was used in 4 patients. rFVIIa was not administered or was administered at a very low dose (20 mg) to 3 and 1 patient, respectively, and bleeding stopped as inhibitor titers decreased and disappeared in these patients. Inhibitors did not disappear in 1 patient and the control of hemostasis became poor and was accompanied by intestinal hemorrhage. Although a large amount of rFVIIa (265 mg in total) was administered, the patient bled to death. Therefore, bleeding may be stopped without the administration of rFVIIa in some AHA cases, while the dose of rFVIIa is not necessarily related to hemostatic effects in other cases. Since the main aim of AHA treatments is the removal of inhibitors, caution is needed to ensure that more than the necessary amount of rFVIIa is not administered. Dove Medical Press 2016-11-03 /pmc/articles/PMC5098745/ /pubmed/27843336 http://dx.doi.org/10.2147/IJGM.S118422 Text en © 2016 Saito et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Saito, Makoto
Kanaya, Minoru
Izumiyama, Koh
Mori, Akio
Irie, Tatsuro
Tanaka, Masanori
Morioka, Masanobu
Ieko, Masahiro
Treatment of bleeding in acquired hemophilia A with the proper administration of recombinant activated factor VII: single-center study of 7 cases
title Treatment of bleeding in acquired hemophilia A with the proper administration of recombinant activated factor VII: single-center study of 7 cases
title_full Treatment of bleeding in acquired hemophilia A with the proper administration of recombinant activated factor VII: single-center study of 7 cases
title_fullStr Treatment of bleeding in acquired hemophilia A with the proper administration of recombinant activated factor VII: single-center study of 7 cases
title_full_unstemmed Treatment of bleeding in acquired hemophilia A with the proper administration of recombinant activated factor VII: single-center study of 7 cases
title_short Treatment of bleeding in acquired hemophilia A with the proper administration of recombinant activated factor VII: single-center study of 7 cases
title_sort treatment of bleeding in acquired hemophilia a with the proper administration of recombinant activated factor vii: single-center study of 7 cases
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5098745/
https://www.ncbi.nlm.nih.gov/pubmed/27843336
http://dx.doi.org/10.2147/IJGM.S118422
work_keys_str_mv AT saitomakoto treatmentofbleedinginacquiredhemophiliaawiththeproperadministrationofrecombinantactivatedfactorviisinglecenterstudyof7cases
AT kanayaminoru treatmentofbleedinginacquiredhemophiliaawiththeproperadministrationofrecombinantactivatedfactorviisinglecenterstudyof7cases
AT izumiyamakoh treatmentofbleedinginacquiredhemophiliaawiththeproperadministrationofrecombinantactivatedfactorviisinglecenterstudyof7cases
AT moriakio treatmentofbleedinginacquiredhemophiliaawiththeproperadministrationofrecombinantactivatedfactorviisinglecenterstudyof7cases
AT irietatsuro treatmentofbleedinginacquiredhemophiliaawiththeproperadministrationofrecombinantactivatedfactorviisinglecenterstudyof7cases
AT tanakamasanori treatmentofbleedinginacquiredhemophiliaawiththeproperadministrationofrecombinantactivatedfactorviisinglecenterstudyof7cases
AT moriokamasanobu treatmentofbleedinginacquiredhemophiliaawiththeproperadministrationofrecombinantactivatedfactorviisinglecenterstudyof7cases
AT iekomasahiro treatmentofbleedinginacquiredhemophiliaawiththeproperadministrationofrecombinantactivatedfactorviisinglecenterstudyof7cases